Top

European Journal of Drug Metabolism and Pharmacokinetics

Published in:

01-02-2018 | Short Communication

Biocomparison Study of Adult and Paediatric Dose Strengths of the Prostacyclin Receptor Agonist Selexipag

Authors: Margaux Boehler, Shirin Bruderer, Ivan Ulč, Jasper Dingemanse

Published in: European Journal of Drug Metabolism and Pharmacokinetics | Issue 1/2018

Abstract

Background and objectives

Selexipag is an oral, non-prostanoid, selective prostacyclin receptor agonist recently marketed for the treatment of pulmonary arterial hypertension (PAH) in adults. Selexipag may also be an effective treatment in children with PAH. The aim of this study was to compare the pharmacokinetics of selexipag and its active metabolite ACT-333679 following single oral administration of one tablet of 200 µg selexipag (Treatment A) vs. 4 paediatric tablets of 50 µg (Treatment B) in healthy adult male subjects.

Methods

This was an open-label, randomized, two-treatment, two-period, crossover biocomparison study. Bioequivalence criteria were explored and safety variables (vital signs, electrocardiogram, and laboratory parameters) were assessed.

Results

The exploratory analysis showed that the 90% confidence intervals of geometric mean ratio (Treatment B/Treatment A) for maximum plasma concentration (C _max), area under the plasma concentration–time curve from zero to infinity (AUC_0–∞) of ACT-333679, as well as AUC_0–∞ of selexipag, were within the bioequivalence interval (0.80, 1.25). In addition, no relevant difference in C _max for selexipag between the two treatments can be concluded. Single oral dose administration of 200 µg selexipag as one tablet of 200 µg or four tablets of 50 µg was well tolerated.

Conclusions

Pharmacokinetic characteristics of selexipag and its metabolite ACT-333679 following administration of one adult tablet of 200 µg selexipag and four paediatric tablets of 50 µg selexipag were comparable.

Trial registration

ClinicalTrials.gov identifier: NCT02745860.

Available only for authorised users

Farber HW, Loscalzo J. Pulmonary arterial hypertension. N Engl J Med. 2004;351(16):1655–65.CrossRefPubMed

Wort SJ, Woods M, Warner TD, Evans TW, Mitchell JA. Cyclooxygenase-2 acts as an endogenous brake on endothelin-1 release by human pulmonary artery smooth muscle cells: implications for pulmonary hypertension. Mol Pharmacol. 2002;62(5):1147–53.CrossRefPubMed

Dorris SL, Peebles RS Jr. PGI2 as a regulator of inflammatory diseases. Mediators Inflamm. 2012;2012:926968.CrossRefPubMedPubMedCentral

Kuwano K, Hashino A, Asaki T, Hamamoto T, Yamada T, Okubo K, et al. 2-[4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy]-N-(methylsulfonyl)acetamide (NS-304), an orally available and long-acting prostacyclin receptor agonist prodrug. J Pharmacol Exp Ther. 2007;322(3):1181–8.CrossRefPubMed

EMA. Selexipag (UPTRAVI): annex I, summary of product characteristics. February 2017.

FDA. Highlights of Prescribing Information: Uptravi^® (selexipag) tablets, for oral use. http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207947s000lbl.pdf. December 2015.

Sitbon O, Channick R, Chin KM, Frey A, Gaine S, Galie N, et al. Selexipag for the treatment of pulmonary arterial hypertension. N Engl J Med. 2015;373(26):2522–33.CrossRefPubMed

Baldoni D, Bruderer S, Muhsen N, Dingemanse J. Bioequivalence of different dose-strength tablets of selexipag, a selective prostacyclin receptor agonist, in a multiple-dose up-titration study. Int J Clin Pharmacol Ther s. 2015;53(9):788–98.CrossRef

Barst RJ, Ertel SI, Beghetti M, Ivy DD. Pulmonary arterial hypertension: a comparison between children and adults. Eur Respir J. 2011;37(3):665–77.CrossRefPubMedPubMedCentral

10.

Abman SH, Hansmann G, Archer SL, Ivy DD, Adatia I, Chung WK, et al. Pediatric pulmonary hypertension: guidelines from the american heart association and american thoracic society. Circulation. 2015;132(21):2037–99.CrossRefPubMed

11.

Hansmann G, Apitz C. Treatment of children with pulmonary hypertension. Expert consensus statement on the diagnosis and treatment of paediatric pulmonary hypertension. The European Paediatric Pulmonary Vascular Disease Network, endorsed by ISHLT and DGPK. Heart. 2016;102 Suppl 2:ii67–85.

12.

FDA. Guidance for industry: E11 Clinical investigation of medicinal products in the pediatric population. https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM073143.pdf. December 2000.

13.

FDA. Draft Guidance for industry: General Clinical Pharmacology Considerations for Pediatric Studies for Drugs and Biological Products. https://www.fda.gov/downloads/drugs/guidances/ucm425885.pdf. December 2014.

14.

Gibaldi M, Perrier D. Pharmacokinetics. 2nd ed. New York: Marcel Dekker; 1982.

15.

Kaufmann P, Niglis S, Bruderer S, Segrestaa J, Aanismaa P, Halabi A, et al. Effect of lopinavir/ritonavir on the pharmacokinetics of selexipag an oral prostacyclin receptor agonist and its active metabolite in healthy subjects. Br J Clin Pharmacol. 2015;80(4):670–7.CrossRefPubMedPubMedCentral

16.

FDA. Guidance for Industry: Bioavailability and Bioequivalence Studies for Orally Administered Drug Products-General Considerations. http://www.fda.gov/ohrms/dockets/ac/03/briefing/3995B1_07_GFI-BioAvail-BioEquiv.pdf. March 2003, Revision 1.

17.

EMA. Committee for medicinal products for human use: Guideline on the investigation of bioequivalence. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/01/WC500070039.pdf. January 2010.

18.

Bruderer S, Hurst N, Kaufmann P, Dingemanse J. Multiple-dose up-titration study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of selexipag, an orally available selective prostacyclin receptor agonist, in healthy subjects. Pharmacology. 2014;94(3–4):148–56.CrossRefPubMed

19.

Kaufmann P, Okubo K, Bruderer S, Mant T, Yamada T, Dingemanse J, et al. Pharmacokinetics and Tolerability of the novel oral prostacyclin IP receptor agonist selexipag. Am J Cardiovasc Drugs. 2015;15(3):195–203.CrossRefPubMedPubMedCentral

20.

Matalova P, Urbanek K, Anzenbacher P. Specific features of pharmacokinetics in children. Drug Metab Rev. 2016;48(1):70–9.CrossRefPubMed

21.

Hines RN. The ontogeny of drug metabolism enzymes and implications for adverse drug events. Pharmacol Ther. 2008;118(2):250–67.CrossRefPubMed

22.

Hines RN. Developmental expression of drug metabolizing enzymes: impact on disposition in neonates and young children. Int J Pharm. 2013;452(1–2):3–7.CrossRefPubMed

23.

Song G, Sun X, Hines RN, McCarver DG, Lake BG, Osimitz TG, et al. Determination of human hepatic CYP2C8 and CYP1A2 Age-dependent expression to support human health risk assessment for early ages. Drug Metab Dispos. 2017;45(5):468–75.CrossRefPubMed

24.

Zhu HJ, Appel DI, Jiang Y, Markowitz JS. Age- and sex-related expression and activity of carboxylesterase 1 and 2 in mouse and human liver. Drug Metab Dispos. 2009;37(9):1819–25.CrossRefPubMed

25.

Shi D, Yang D, Prinssen EP, Davies BE, Yan B. Surge in expression of carboxylesterase 1 during the post-neonatal stage enables a rapid gain of the capacity to activate the anti-influenza prodrug oseltamivir. J Infect Dis. 2011;203(7):937–42.CrossRefPubMedPubMedCentral

26.

Yang D, Pearce RE, Wang X, Gaedigk R, Wan YJ, Yan B. Human carboxylesterases HCE1 and HCE2: ontogenic expression, inter-individual variability and differential hydrolysis of oseltamivir, aspirin, deltamethrin and permethrin. Biochem Pharmacol. 2009;77(2):238–47.CrossRefPubMed

27.

Strassburg CP, Strassburg A, Kneip S, Barut A, Tukey RH, Rodeck B, et al. Developmental aspects of human hepatic drug glucuronidation in young children and adults. Gut. 2002;50(2):259–65.CrossRefPubMedPubMedCentral

28.

Oo C, Hill G, Dorr A, Liu B, Boellner S, Ward P. Pharmacokinetics of anti-influenza prodrug oseltamivir in children aged 1-5 years. Eur J Clin Pharmacol. 2003;59(5–6):411–5.CrossRefPubMed

29.

Batchelor HK, Marriott JF. Formulations for children: problems and solutions. Br J Clin Pharmacol. 2013;79(3):405–18.CrossRef

Title: Biocomparison Study of Adult and Paediatric Dose Strengths of the Prostacyclin Receptor Agonist Selexipag
Authors: Margaux Boehler
Shirin Bruderer
Ivan Ulč
Jasper Dingemanse
Publication date: 01-02-2018
Publisher: Springer International Publishing
Published in: European Journal of Drug Metabolism and Pharmacokinetics / Issue 1/2018
Print ISSN: 0378-7966
Electronic ISSN: 2107-0180
DOI: https://doi.org/10.1007/s13318-017-0424-z

At a glance: The STEP trials

Springer Medicine

Biocomparison Study of Adult and Paediatric Dose Strengths of the Prostacyclin Receptor Agonist Selexipag

Abstract

Background and objectives

Methods

Results

Conclusions

Trial registration

At a glance: The STEP trials

Springer Medicine

Abstract

Background and objectives

Methods

Results

Conclusions

Trial registration

Please log in to get access to this content

Other articles of this Issue 1/2018

Population Pharmacokinetic Modeling of Diltiazem in Chinese Renal Transplant Recipients

Is RPMI 2650 a Suitable In Vitro Nasal Model for Drug Transport Studies?

Population Pharmacokinetic Analysis of Bisoprolol in Patients with Stable Coronary Artery Disease

Pharmacogenetics of Cannabinoids

Absorption, Distribution, Metabolism, and Excretion of [14C]-Volixibat in Healthy Men: Phase 1 Open-Label Study

Population Pharmacokinetics of Combined Intravenous and Local Intrathecal Administration of Meropenem in Aneurysm Patients with Suspected Intracranial Infections After Craniotomy